A recent study published in Nature Genetics has analyzed over 60,000 clinical cancer samples to investigate how the dosage of gene mutations—specifically the total copy number and mutation multiplicity—affects cancer prognosis and metastatic tropism. The researchers developed a Bayesian model called INCOMMON (inference of copy number and mutation multiplicity for oncology) to infer these metrics for each mutation.
The study found that the copy number and multiplicity of mutations in key cancer genes are associated with patient outcomes and the organs to which cancers spread. For example, certain mutations with specific dosage patterns were linked to worse overall survival, while others correlated with a higher likelihood of metastasis to particular sites such as the brain or liver.
According to the authors, this approach provides a more nuanced understanding of how mutations drive cancer behavior beyond simple presence or absence. The findings could help refine prognostic models and guide treatment decisions based on the specific genetic makeup of a tumor.
The study was led by researchers from the University of California, San Francisco, and involved collaboration with multiple institutions. The data were derived from clinical samples collected through the UCSF500 cancer gene panel, which includes targeted sequencing of hundreds of cancer-related genes.
While the study is observational, the authors emphasize that the INCOMMON tool is publicly available and could be applied to other large-scale cancer genomics datasets to further validate and extend these findings.
